Video

Paul Kaufman on Unmet Needs for Glaucoma, Burgeoning Solutions

Author(s):

In the second leg of a weighty interview, Kaufman ruminates on what more is needed.

In this second installment of our conversation, the esteemed Paul Kaufman, MD spoke of unmet needs for the glaucoma patients, including a lack of ophthalmologists that ranges from tens of thousands to one patient in wealthy nations all the way up to millions to one in other places. He also spoke of ways to innovate in the clinical treatment of the disease, including harnessing viruses as ophthalmologic tools.

Kaufman is the Chair-Emeritus of the Department of Ophthalmology & Visual Sciences at the University of Wisconsin School of Medicine and Public Health, in addition to being the former President and Executive Vice President of the Association for Research in Vision and Ophthalmology (ARVO). At ARVO 2017, he delivered a keynote lecture on glaucoma and presbyopia and was awarded Friedenwald Award for his work.

Despite decades in the business, countless accolades and titles, and over 350 published studies, one would be hard-pressed to find someone as thoughtful, focused, and humble about their work. In advance of his lecture and award presentation, Kaufman sat down with MD Magazine for an expansive interview about his motivations, career, and how he sees ophthalmology evolving over time.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.